沙库巴曲缬沙坦对射血分数降低心力衰竭患者超声、生化、临床方面的短期疗效

Short-term effect of Sacubitril/Valsartan in the heart failure patients with reduced of ejection fraction on echocardiography,biochemical and clinical

目的从超声、生化、临床方面探讨沙库巴曲缬沙坦对射血分数降低心力衰竭(HFrEF)患者心功能改善的短期疗效。方法选择2018年6月~2019年9月在我院首诊为HFrEF的患者为研究对象,共20例,年龄51.4±9.923岁,规律服用血管紧张素转化酶抑制剂依那普利3月后换用沙库巴曲缬沙坦继续治疗3月。自身前后对比,分别比较患者确诊时、依那普利治疗3月时和换用沙库巴曲缬沙坦治疗3月后N末端脑钠肽前体、经胸超声心动图测定左室射血分数、6 min步行实验和纽约心功能分级。结果沙库巴曲缬沙坦治疗3月后患者左室射血分数的增幅大于依那普利治疗3月后对比于确诊时的增幅(P<0.05),沙库巴曲缬沙坦治疗3月后患者N末端脑钠肽前体的降幅大于依那普利治疗3月后对比于确诊时的降幅(P<0.05);同时患者使用2类药物后6 min步行实验、纽约心功能分级均有改善,差异有统计学意义(P<0.05),且沙库巴曲缬沙坦改善程度大于依那普利。结论沙库巴曲缬沙坦对射血分数降低心力衰竭患者心功能改善方面的短期疗效(3月)优于依那普利。

Objective To investigate the short-term functionality efficacy of Sacubitril/Valsartan in heart failure patients with reduced ejection fraction(HFrEF)on echocardiography,biochemical and clinical.Methods Twenty HFrEF patients who were first diagnosed in our hospital from June 2018 to September 2019 were selected,with age of 51.4±9.923 years old.Patients were regularly treated with ACEI(angiotensin-converting enzyme inhibitor)Enalapril for 3 months and then switched to Sacubitril/Valsartan for 3 months.The effect of the two medication between the baseline and 3 months after Enalapril treatment,and 3 months after switching to Sacubitril/Valsartan for N-terminal brain natriuretic peptide,left ventricular ejection fraction measured by transthoracic echocardiography,and 6 min walking test and New York Heart Association(NYHA)scale assessment were compared.Results After 3 months of treatment with Sacubitril/Valsartan,the increasing amplitude of left ventricular ejection fraction in patients was greater than the before(P<0.05).The decreasing amplitude of N-terminal brain natriuretic peptide after 3 months of treatment with Sacubitril/Valsartan was greater than that after 3 months of treatment with Enalapril(P<0.05).The difference in the improvement of distance walked on the 6 min walk test and NYHA scale significant(P<0.05).Conclusion The short-term(3 months)functionality efficacy of Sacubitril/Valsartan in HFrEF patients is better than that of Enalapril.